CELEX: 32004M3399
Language: en
Date: 2004-03-23 00:00:00
Title: Commission Decision of 23/03/2004 declaring a concentration to be compatible with the common market (Case No COMP/M.3399 - PPM VENTURES / TRITON / PHARMACIA DIAGNOSTICS) according to Council Regulation (EEC) No 4064/89 (Only the English text is authentic)

Avis juridique important

|

32004M3399

Commission Decision of 23/03/2004 declaring a concentration to be compatible with the common market (Case No IV/M.3399 - PPM VENTURES / TRITON / PHARMACIA DIAGNOSTICS) according to Council Regulation (EEC) No 4064/89 (Only the English text is authentic)  

Official Journal 082 , 01/04/2004 P. 0004 - 0004

Commission Decision of 23/03/2004 declaring a concentration to be compatible with the common market (Case No IV/M.3399 - PPM VENTURES / TRITON / PHARMACIA DIAGNOSTICS) according to Council Regulation (EEC) No 4064/89 (Only the English text is authentic)To the notifying parties  Dear Madam(s) and/or Sir(s),Subject: Case No. COMP/M.3399 - PPMV/Triton/Pharmacia Diagnostics Notification of 24/02/2004 pursuant to Article 4 of Council Regulation (EEC) No. 4064/89 [1], as last amended by Regulation (EC) No 1310/97 [2] Publication in the Official Journal of the European Union No. C 55, 03.03.2004 Page 7[1]  OJ L 395, 30.12.1989 p. 1; corrigendum: OJ L 257, 21.9.1990, p. 13.[2]   OJ L 180, 9. 7. 1997, p.  1; corrigendum OJ L 40, 13.2.1998, p. 17.1. On 24/02/2004, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No. 4064/89 by which the undertakings PPM Ventures Ltd ('PPMV', UK), belonging to the Prudential Plc group, and Triton Managers Ltd ('Triton', UK) acquire within the meaning of Article 3(1)(b) of the Council Regulation joint control of  the Pharmacia Diagnostics business (Sweden), belonging to Pfizer Inc.(' Pfizer', USA), by way of  purchase of shares.2. The business activities of the undertakings concerned are : - for undertaking PPMV : Private equity investment fund - for undertaking Triton : Private equity investment fund- for undertaking Pharmacia Diagnostics : blood test systems for clinical diagnosis and   monitoring of allergy, asthma and autoimmune diseases; natural allergen raw materials and pollen extracts for natural health products3. After examination of the notification, the Commission has concluded that the notified operation falls within the scope of Council Regulation (EEC) No. 4064/89 and of paragraph 4, subparagraph b, of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No 4064/89 [3].  [3]   OJ C 217, 29.07.2000, p. 32.4. For the reasons set out in the Notice on a simplified procedure, the Commission has decided not to oppose the notified operation and to declare it compatible with the common market and with the EEA Agreement.  This decision is adopted in application of Article 6(1)(b) of Council Regulation (EEC) No. 4064/89.For the Commission(signed)  Mario MONTI Member of the Commission